Interferon-Based Biopharmaceuticals: Overview on the Production, Purification, and Formulation

Area of Science:

• Biotechnology and Pharmaceutical Sciences
• Molecular Biology and Genetics
• Immunology

Background:

• Biopharmaceuticals, particularly therapeutic proteins and antibodies, have significantly advanced disease treatment since the 1980s.
• Recombinant DNA technology enables high-specificity protein production, driving pharmaceutical biotechnology success.
• Interferons, discovered in 1957, are key biopharmaceuticals with broad clinical applications against viral infections, cancers, and multiple sclerosis.

Purpose of the Study:

• To provide a comprehensive overview of the manufacturing evolution of interferons.
• To discuss advancements in interferon production, purification, and formulation.
• To highlight key developments in upstream, downstream, and delivery processes for biopharmaceutical interferons.

Main Methods:

• Review of scientific literature on interferon manufacturing processes.
• Analysis of developments in genetic engineering for host and vector systems.
• Examination of purification techniques including chromatography and novel methods like aqueous two-phase systems.
• Assessment of formulation strategies for improved bioactivity and targeted delivery.

Main Results:

• Significant progress in upstream processing through optimized gene expression, host systems, and culture conditions.
• Advancements in downstream processing with enhanced chromatographic techniques and alternative separation methods.
• Development of improved formulations leading to enhanced bioactivity, extended half-lives, and targeted delivery of interferons.

Conclusions:

• The evolution of interferon manufacturing has significantly improved the production and therapeutic potential of these vital biopharmaceuticals.
• Continued research and development in biopharmaceutical manufacturing hold promise for future advancements in treating complex diseases.
• Optimized production, purification, and formulation are critical for maximizing the clinical benefits of interferons.